Adapttech is a biomedical company that brings smart technologies to market, in order to improve the quality of life of people with physical limitations. Our main product, the INSIGHT System, is a combined interior-socket 3D scanner, patient wearable, and iPad app to analyse residual limb-socket fittings. The purpose of the technology is to improve the efficiency of the fitting process to rapidly deliver an ultra-comfortable and uniquely-fitted prosthesis for the patient. This innovative combination of 3D scanner, sensor and software technology empowers clinicians to accurately fit lower limb prosthesis and monitor patients’ rehabilitation process in a faster and easier way. Adapttech aims to improve the life of lower limb amputees.
Asgard Therapeutics AB was founded in December 2018 as a spin-off from Lund University in Sweden. Asgard is a pre-clinical stage, biotech startup company pioneering the use of cellular reprogramming in cancer immunotherapy. The scientific founders of Asgard Therapeutics have developed a cellular reprogramming technology that forces cancer cells to present their own antigens to the immune system, triggering cancer cell-specific immune responses that lead to cancer clearance. Asgard solution, TrojanDC, is an off-the-shelf cancer immunotherapy that can be administered to multiple patients inducing a personalised immune response. Moreover, it can be applied to a multitude of solid cancers, representing a platform technology with vast economic potential.
BSIM Therapeutics is a biotech company focused on the design of organ-targeted, high-quality drug candidates for the treatment of life-threatening transthyretin-mediated amyloidosis and neurodegenerative diseases. BSIM works closely with patients and physicians to understand and answer to multiple clinical manifestations of these pathologies, some of which represent unmet medical needs. BSIM is strongly committed to advance its best candidate to clinical development, and thus reach clinical proof of concept within 3 years.
Cellmabs groundbreaking research in the field of Glycobiology and Oncobiology led to the discovery of a novel class of antibodies that target tumor-specific antigens present only in solid tumors and not on normal cells. Cellmabs is currently developing innovative immunotherapies and adoptive T cell therapies (CAR-T cells) for treating patients with unmet needs in the field of Oncology.
Delox is a spin-off from the Faculty of Sciences of the University of Lisbon that developed a novel dry formulation of hydrogen peroxide for bio-decontamination. This patented formulation can be incorporated into devices to decontaminate hospitals, laboratories and pharmaceutical products. Our mission is to deliver an affordable sterilization system to everyone, everywhere.
GlyCardial Diagnostics is a Barcelona-based spin-off company of the Sant Pau Hospital Research Institute and CSIC (Spanish National Research Council) focused on the development of a novel in vitro diagnostic (IVD) test for the detection of Apo J-Glyc blood levels for the early diagnosis of cardiac ischemia and the prediction of patient’s evolution. Acute ischemic events are the most common cardiac emergencies with substantial morbidity and mortality worldwide. However, there are no available biomarkers for the early diagnosis of ischemia which is essential to prevent irreversible myocardial damage. Our goal is to bring to a market-ready stage the first IVD for the early detection of ischemia.
Immunethep discovered a novel mechanism used by different pathogenic bacteria to suppress host immune response. Immunethep develops broad coverage anti-bacterial Immunotherapies that target this virulence mechanism. Immunethep pipeline includes a preventive vaccine (ready to start Clinical trials) and Monoclonal Antibodies (in development phase) to address infections from five different bacteria E. coli, K. pneumoniae, S. aureus, S. Pneumoniae and GBS.
Performetric is a platform that uses the Human Computer Interaction (HCI) for analysis of human behaviors in real time and non-invasively, such as mental fatigue, computer game cheating behaviors or digital identity for different contexts.
Mediceus is building a large-scale database of anonymized health records, and, through the use of big data analyses and advanced machine learning techniques, is extracting new scientific knowledge to treat patients better. The patient is given full control over their data. They may access it, share it, and even delete it, all through a user-friendly mobile app.
Tonic App is the mobile platform that helps medical doctors on their day-to-day work, by aggregating the best professional resources. Doctors save time and can focus on what is really important: their patients.
Proterris is a Lisbon/Boston based, low-dose CO therapeutics company developing both inhaled (“iCO”) and CO-releasing molecule (“CORMs”) applications to treat a variety of transplant, oncology, fibrotic and inflammatory diseases. Proterris is P2b/3 ready with iCO in kidney and lung transplant, is developing CORM-Abs and NanoCORMs for oncology and rheumatoid arthritis, and is developing other CORMs for NASH. With operations divided equally between Lisbon and Boston, Proterris is seeking to close its final Series A tranche of $20-25M to complete its P2b studies in kidney and lung transplant and to render its CORM-Abs, NanoCORMs and NASH CORMs IND-ready.
Vaxdyn owns a technological platform for development of vaccines against the most urgent threats causing antibiotic-resistant infections. The technology has overcome potential barriers for development of these type of vaccines, and it has been validated by the sponsorship of organizations specialized on vaccine development, which have committed investment until completion of clinical Phase I. With them we are working on overcoming commercial barriers. The technology has been adapted for delivering multivalent vaccines, which could prevent colonization and infection by several bacterial pathogens with only one product, in order to facilitate the uptake of the vaccine by already established programs in healthcare organizations. Our lead product is targeting population at risk of development pneumonia and sepsis produced by the top three resistant pathogens. Vaxdyn is looking for investment to complement the funding committed by international organizations.
Exogenus Therapeutics is a drug development company using exosomes as a tool to develop innovative therapeutic products. Exogenus’ technology makes use of Umbilical Cord Blood cells to produce its lead API (Exo-101), which has regenerative, anti-inflammatory and immunomodulatory properties. Having demonstrated the safety and regenerative effect of Exo-101 for wound healing, Exogenus is now exploring its potential for the treatment of Inflammatory and Autoimmune Diseases.